Search Results

• • 293 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Regarding the study testing the addition of gemcitabine to concurrent chemoradiotherapy in cervical carcinoma: clarity needed

  Authors:Swaroop Revannasiddaiah, Madhup Rastogi, Manoj Gupta, and Rajeev SeamFrom:Indian Journal of Medical and Paediatric Oncology (Vol. 34, Issue 1) Peer-Reviewed

  January-March 2013528 words Letter to the editor 1390LByline: Swaroop. Revannasiddaiah, Madhup. Rastogi, Manoj. Gupta, Rajeev. Seam Sir, Having read the article titled, "Addition of gemcitabine to standard therapy in locally advanced cervical cancer: A randomized...

• Carotid artery inflammation associated with gemcitabine-based therapy: a special report

  Authors:Alexandre Chan, Mingjun Song, Mark Ryan De Guzman Langit, Teh Aun Lim, Warren Fong, Kevin Tay, et al.From:Future Oncology (Vol. 11, Issue 14) Peer-Reviewed

  July 20154,724 words Clinical report 1490LAuthor(s): Alexandre Chan aff1 aff2 , Mingjun Song aff3 , Mark Ryan De Guzman Langit aff1 , Teh Aun Lim aff4 , Warren Fong aff5 , Kevin Tay aff3 , Soon Thye Lim aff3 , Tiffany Tang [*] aff3 KEYWORDS carotid...

• Gemcitabine: interstitial pneumonitis in an elderly patient: case report

  From:Reactions Weekly (Issue 1312)

  July 31, 2010203 words Brief article 980L[S] A 70-year-old man developed interstitial pneumonitis during gemcitabine therapy for bile duct cancer. The man, who had undergone pancreaticoduodenectomy in August 2007 for stage I lower bile duct cancer,...

• Antibacterials/gemcitabine/griseofulvin: Linear IgA bullous dermatosis (first report with griseofulvin): 4 case reports

  From:Reactions Weekly (Issue 1316)

  Aug. 28, 2010160 words Brief article, Case ... 1000L[*] In a study involving 16 patients (aged 24--80 years; eight men and eight women), four patients developed drugassociated linear IgA bullous dermatosis (LABD). The patients experienced LABD during treatment with...

• HuR modulates gemcitabine efficacy: new perspectives in pancreatic cancer treatment

  Authors:Raphael Marechal and Jean-Luc Van LaethemFrom:Expert Review of Anticancer Therapy (Vol. 9, Issue 10) Peer-Reviewed

  Oct. 20092,091 words Report Author(s): Raphaël Maréchal 1 , Jean-Luc Van Laethem [[dagger]] 2 Keywords: deoxycytidine kinase; gemcitabine; Hu antigen R; pancreatic adenocarcinoma Gemcitabine, a 2´2´-difluoro-2´-deoxycytidine analog, is...

• Role of gemcitabine in cancer therapy

  Authors:L Toschi, G Finocchiaro, S Bartolini, V Gioia, and F CappuzzoFrom:Future Oncology (Vol. 1, Issue 1) Peer-Reviewed

  Feb. 20057,883 words Drug overview Author(s): L Toschi 1 , G Finocchiaro 2 , S Bartolini 3 , V Gioia 4 , F Cappuzzo [[dagger]] 5 Keywords: cancer; chemotherapy; gemcitabine During the last few years, several new chemotherapy compounds have...

• Algorithmic Modeling Quantifies the Complementary Contribution of Metabolic Inhibitions to Gemcitabine Efficacy

  Authors:Ozan Kahramanogullari, Gianluca Fantaccini, Paola Lecca, Daniele Morpurgo, and Corrado PriamiFrom:PLoS ONE (Vol. 7, Issue 12) Peer-Reviewed

  Dec. 11, 20127,771 words Article 1570LAuthor(s): Ozan Kahramanogullari 1 , * , Gianluca Fantaccini 1 , Paola Lecca 1 , Daniele Morpurgo 1 , Corrado Priami 1 , 2 Introduction Gemcitabine (2,2-difluorodeoxycytidine, dFdC) is a prodrug, which is commonly...

• Preoperative gemcitabine based chemo-radiotherapy in locally advanced non metastatic pancreatic adenocarcinoma

  Authors:Doaa W. Maximous, Mostafa E. Abdel-Wanis, Mohammed I. El-Sayed, and Alaa A. Abd-ElsayedFrom:International Archives of Medicine (Vol. 2, Issue 7) Peer-Reviewed

  Mar. 27, 20092,872 words Report Authors: Doaa W Maximous [1]; Mostafa E Abdel-Wanis [2]; Mohammed I El-Sayed [2]; Alaa A Abd-Elsayed (corresponding author) [3] Introduction Almost 30% of patients with pancreatic cancer have locally advanced...

• Honokiol Arrests Cell Cycle, Induces Apoptosis, and Potentiates the Cytotoxic Effect of Gemcitabine in Human Pancreatic Cancer Cells

  Authors:Sumit Arora, Arun Bhardwaj, Sanjeev K. Srivastava, Seema Singh, Steven McClellan, Bin Wang, et al.From:PLoS ONE (Vol. 6, Issue 6) Peer-Reviewed

  June 24, 20116,103 words Article 1520LSurvival rates for patients with pancreatic cancer are extremely poor due to its asymptomatic progression to advanced and metastatic stage for which current therapies remain largely ineffective. Therefore, novel...

• Plasma pharmacokinetics after combined therapy of gemcitabine and oral S-1 for unresectable pancreatic cancer

  Authors:Bunzo Nakata, Ryosuke Amano, Shigetomi Nakao, Tatsuro Tamura, Osamu Shinto, Toshiki Hirakawa, et al.From:Journal of Experimental & Clinical Cancer Research (Vol. 29) Peer-Reviewed

  Feb. 24, 20103,622 words Report Background The combination of gemcitabine (GEM) and S-1, an oral 5-fluorouracil (5-FU) derivative, has been shown to be a promising regimen for patients with unresectable pancreatic cancer. Methods Six patients...

• Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy

  Authors:Miso Kim, Ja Hyeon Ku, Cheol Kwak, Hyeon Hoe Kim, Eunsik Lee, Bhumsuk Keam, et al.From:PLoS ONE (Vol. 10, Issue 7) Peer-Reviewed

  July 22, 20154,535 words Clinical report 1460LPreclinical and clinical studies have suggested that expression of ribonucleotide reductase regulatory subunit M1 (RRM1) and excision repair cross-complementation group 1 (ERCC1) is associated with resistance to...

• A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX chemotherapy

  Authors:Georgios Kaissis, Sebastian Ziegelmayer, Fabian Lohofer, Katja Steiger, Hana Algul, Alexander Muckenhuber, et al.From:PLoS ONE (Vol. 14, Issue 10) Peer-Reviewed

  Oct. 2, 20194,603 words Report 1630LPurpose Development of a supervised machine-learning model capable of predicting clinically relevant molecular subtypes of pancreatic ductal adenocarcinoma (PDAC) from diffusion-weighted-imaging-derived radiomic...

• Gemcitabine: acute coronary syndrome: case report

  From:Reactions Weekly (Issue 1245)

  Mar. 28, 2009399 words Case study [S] A 60-year-old woman developed acute coronary syndrome while receiving gemcitabine for metastatic leiomyosarcoma. Following admission for bilateral pulmonary nodules at aged 59 years, the woman experienced...

• Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer

  Authors:Alice Dewdney and Ian ChauFrom:Advances in Oncology (Vol. 5, Issue 4) Peer-Reviewed

  Dec. 2010872 words Clinical report 1570LCisplatin plus gemcitabine versus gemcitabine for biliary tract cancer Valle J, Wasan H, Palmer DH et al N Engl J Med, 2010, 362, 1273-1281 The majority of biliary tract cancers (BTCs) are diagnosed at an...

• Gemcitabine: toxic erythema: case report

  From:Reactions Weekly (Issue 1284)

  Jan. 16, 2010334 words Brief article, Case ... [S] A 59-year-old man with pancreatic cancer developed toxic erythema during adjuvant chemotherapy with gemcitabine [outcome not clearly stated]. The man underwent pancreatectomy, splenectomy and partial...

• Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: A systematic review. (Original Article)

  Authors:A. Clegg, D.A. Scott, P. Hewitson, M. Sidhu, and N. WaughFrom:Thorax (Vol. 57, Issue 1) Peer-Reviewed

  Jan. 20026,021 words Product/service eval... Background: Lung cancer remains a devastating disease with few effective treatment options. Recent developments in chemotherapy have led to cautious optimism. This paper reviews the evidence an the clinical and cost...

• Effect of genetic polymorphisms on therapeutic response and clinical outcomes in pancreatic cancer patients treated with gemcitabine

  Authors:Hye In Woo, Ka-Kyung Kim, Hangseok Choi, Seonwoo Kim, Kee-Taek Jang, Jun Ho Yi, et al.From:Pharmacogenomics (Vol. 13, Issue 9) Peer-Reviewed

  July 20127,149 words Report 1470LAuthor(s): Hye In Woo 1 , Ka-Kyung Kim 1 2 , Hangseok Choi 3 , Seonwoo Kim 3 , Kee-Taek Jang 4 , Jun Ho Yi 5 , Young Suk Park 5 , Joon Oh Park [*] 7 , Soo-Youn Lee [*] 6 KEYWORDS : CMPK1; gemcitabine;...

• The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer

  Authors:Stefan Boeck and Volker HeinemannFrom:Future Oncology (Vol. 4, Issue 1) Peer-Reviewed

  Feb. 20086,525 words Clinical report Author(s): Stefan Boeck [[dagger]] 1 , Volker Heinemann 2 Keywords: chemotherapy; gemcitabine; pancreatic cancer; refractory; second-line; treatment failure Unresectable pancreatic adenocarcinoma remains a...

• Gemcitabine/WT1 peptide loaded dendritic cell vaccine: injection site reactions in elderly patients: 2 case reports

  From:Reactions Weekly (Issue 1335)

  Jan. 22, 2011454 words Case study 1370L[S] Two 73-year-old women with adenocarcinoma developed injection site reactions during treatment with WT1 peptide loaded dendritic cell vaccine and gemcitabine as part of a phase I clinical trial [time to reaction...

• Progression of Large Lymphoma Is Significantly Impeded with a Combination of Gemcitabine Chemotherapy and Dendritic Cells Intra-Tumor Vaccination.

  Authors:Xue-Jun Zhu, Zhong-Fa Yang, Jin-Yong Zhou, Li Liu, Xue-Mei Sun, Zhen-Fang Fan, et al.From:PLoS ONE (Vol. 10, Issue 7) Peer-Reviewed

  July 16, 20157,922 words Article 1510LRelapsed, refractory lymphoma remains to be a challenge and lacks efficient treatment. Some tumor cells escape from treatment, become resistant to chemotherapeutic agents, and rapidly regenerate into large tumors....